First Controlled Study of Vasomedical's EECP Published in the Journal of the American College of Cardiology -- EECP Cited as Having Great Potential.

WESTBURY, N.Y.--(BW HealthWire)--June 1, 1999--

Results of the Multicenter Study of Enhanced External Counterpulsation (MUST-EECP) were published in the June 1999 issue of the Journal of the 'American College of Cardiology,' showing that EECP reduces angina and extends the time to exercise-induced ischemia in patients with symptomatic coronary artery disease.

Seven nationally renowned university hospital centers participated in this randomized, placebo, controlled trial (Columbia-Presbyterian Medical Center, Columbia University (New York); Moffit-Long Hospital, University of California at San Francisco (San Francisco); Yale University School of Medicine (New Haven, Conn.); Beth Israel Deaconess Medical Center, Harvard University (Boston); Grant/Riverside Methodist Hospitals (Columbus, Ohio); Presbyterian University Hospital, University of Pittsburgh Medical Center (Pittsburgh, Pa.); and Loyola University Medical Center (Maywood, Ill.)). One hundred thirty-nine patients with angina, who had documented coronary artery disease and positive exercise treadmill tests, were randomly assigned thirty-five hours of active or inactive counterpulsation over a four to seven week period.

The results of this study showed that EECP reduces the frequency of angina episodes and increases the length of time before exercise produces electrocardiograph changes indicating insufficient blood supply to the heart muscle.

Vasomedical's Vice President of Clinical Affairs, Anthony E. Peacock remarked, "although EECP has been studied extensively over the last decade, MUST-EECP is the first controlled study that meets today's scientific standards, therefore MUST-EECP is destined to become a new standard by which the efficacy of therapeutic devices are studied. Its publication in the 'Journal of the American College of Cardiology' with an editorial by Dr. C. Richard Conti, past president of the American College of Cardiology, constitutes, therefore, one of the most important milestones in EECP becoming an established, widely available treatment for heart disease."

Since heart disease is the number one health problem in the United States, this is important news to patients seeking treatment for angina. Other therapies available for angina include drug therapy, angioplasty and coronary artery bypass grafting.

The latter two invasive measures are limited by the patient's amenability to such procedures and by increasing risk of mortality with repeat procedures as well as increased treatment failures over time.

EECP is a noninvasive outpatient treatment that is capturing the attention of cardiologists as an alternative to surgical procedures and to help restore a better quality of life to patients whose treatment options otherwise have been exhausted.

The Health Care Financing Administration announced recently that EECP will be covered for Medicare patients after July 1, 1999.

Vasomedical, Inc. (Nasdaq:VASO; www.vasomedical.com) is primarily engaged in designing, manufacturing, marketing and supporting external counterpulsation systems based on the Company's proprietary technology. EECP(R) is a registered trademark of Vasomedical. This system is now in use at major medical centers, including those affiliated with Columbia-Presbyterian Medical Center, University of Pittsburgh, University of California San Diego, University of California San Francisco and the University of Virginia, as well as The Miami Heart Institute and The Mayo Clinic. The Company provides hospitals, clinics and private medical practices EECP(R) equipment, treatment guidance and a staff training and maintenance program to ensure optimal patient outcomes.

Except for the historical information contained in this news release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believe," "estimate," "expect," "intend," and similar expressions, as they relate to the company and its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by, and information currently available to, the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory, reimbursement and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update any forward-looking statements as a result of future events or developments.